Crossmark

Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test

Crossref DOI link: https://doi.org/10.1136/rmdopen-2023-003927

Published Online: 2024-04-10

Published Print: 2024-04

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Di Matteo, Andrea https://orcid.org/0000-0003-0867-7051
Mankia, Kulveer https://orcid.org/0000-0002-7945-6582
Garcia-Montoya, Leticia

Sharrack, Sana https://orcid.org/0009-0004-2436-8229
Duquenne, Laurence https://orcid.org/0000-0001-7631-0986
Nam, Jacqueline L

Mahler, Michael

Emery, Paul https://orcid.org/0000-0002-7429-8482
Funding

Funding for this research was provided by:

BRC (IS-BRC-1215-20015)
License Information

License valid from 2024-04-10